nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—CYP2C18—malignant glioma	0.285	0.396	CbGaD
Lidocaine—EGFR—malignant glioma	0.222	0.309	CbGaD
Lidocaine—CYP2B6—malignant glioma	0.211	0.294	CbGaD
Lidocaine—CYP1A2—Carmustine—malignant glioma	0.0521	0.57	CbGbCtD
Lidocaine—CYP3A4—Temozolomide—malignant glioma	0.0394	0.43	CbGbCtD
Lidocaine—Teratogenicity—Carmustine—malignant glioma	0.00449	0.0893	CcSEcCtD
Lidocaine—Hyperacusis—Temozolomide—malignant glioma	0.00244	0.0485	CcSEcCtD
Lidocaine—Meningitis—Carmustine—malignant glioma	0.00243	0.0483	CcSEcCtD
Lidocaine—Burning sensation—Carmustine—malignant glioma	0.00135	0.0269	CcSEcCtD
Lidocaine—Hyperaesthesia—Temozolomide—malignant glioma	0.00116	0.023	CcSEcCtD
Lidocaine—Petechiae—Temozolomide—malignant glioma	0.00111	0.022	CcSEcCtD
Lidocaine—EGFR—telencephalon—malignant glioma	0.00091	0.0558	CbGeAlD
Lidocaine—Depressed level of consciousness—Carmustine—malignant glioma	0.000909	0.0181	CcSEcCtD
Lidocaine—Urinary incontinence—Carmustine—malignant glioma	0.000909	0.0181	CcSEcCtD
Lidocaine—Skin exfoliation—Carmustine—malignant glioma	0.000899	0.0179	CcSEcCtD
Lidocaine—Neuropathy—Carmustine—malignant glioma	0.000884	0.0176	CcSEcCtD
Lidocaine—Depressed level of consciousness—Temozolomide—malignant glioma	0.000878	0.0175	CcSEcCtD
Lidocaine—Urinary incontinence—Temozolomide—malignant glioma	0.000878	0.0175	CcSEcCtD
Lidocaine—Chloroprocaine—SLC6A3—malignant glioma	0.000869	0.292	CrCbGaD
Lidocaine—Skin exfoliation—Temozolomide—malignant glioma	0.000869	0.0173	CcSEcCtD
Lidocaine—Ropivacaine—CYP2B6—malignant glioma	0.000867	0.291	CrCbGaD
Lidocaine—Coma—Carmustine—malignant glioma	0.00086	0.0171	CcSEcCtD
Lidocaine—Neuropathy—Temozolomide—malignant glioma	0.000854	0.017	CcSEcCtD
Lidocaine—Chloroprocaine—BCHE—malignant glioma	0.000833	0.279	CrCbGaD
Lidocaine—Diplopia—Carmustine—malignant glioma	0.000683	0.0136	CcSEcCtD
Lidocaine—SCN2A—brainstem—malignant glioma	0.000666	0.0409	CbGeAlD
Lidocaine—Diplopia—Temozolomide—malignant glioma	0.00066	0.0131	CcSEcCtD
Lidocaine—SCN2A—telencephalon—malignant glioma	0.000591	0.0363	CbGeAlD
Lidocaine—Dysphagia—Carmustine—malignant glioma	0.000591	0.0117	CcSEcCtD
Lidocaine—Dysphagia—Temozolomide—malignant glioma	0.000571	0.0113	CcSEcCtD
Lidocaine—SCN10A—telencephalon—malignant glioma	0.00057	0.035	CbGeAlD
Lidocaine—Sweating increased—Temozolomide—malignant glioma	0.000556	0.011	CcSEcCtD
Lidocaine—SCN9A—midbrain—malignant glioma	0.000538	0.033	CbGeAlD
Lidocaine—SCN9A—spinal cord—malignant glioma	0.000525	0.0322	CbGeAlD
Lidocaine—SCN3A—telencephalon—malignant glioma	0.00052	0.0319	CbGeAlD
Lidocaine—Neuropathy peripheral—Carmustine—malignant glioma	0.000516	0.0103	CcSEcCtD
Lidocaine—Stomatitis—Carmustine—malignant glioma	0.000513	0.0102	CcSEcCtD
Lidocaine—EGFR—cerebellum—malignant glioma	0.000505	0.031	CbGeAlD
Lidocaine—Neuropathy peripheral—Temozolomide—malignant glioma	0.000499	0.00991	CcSEcCtD
Lidocaine—Stomatitis—Temozolomide—malignant glioma	0.000496	0.00986	CcSEcCtD
Lidocaine—Haemoglobin—Carmustine—malignant glioma	0.000475	0.00944	CcSEcCtD
Lidocaine—Haemorrhage—Carmustine—malignant glioma	0.000473	0.0094	CcSEcCtD
Lidocaine—Hypoaesthesia—Carmustine—malignant glioma	0.00047	0.00935	CcSEcCtD
Lidocaine—SCN2A—medulla oblongata—malignant glioma	0.000465	0.0285	CbGeAlD
Lidocaine—Haemoglobin—Temozolomide—malignant glioma	0.000459	0.00913	CcSEcCtD
Lidocaine—Haemorrhage—Temozolomide—malignant glioma	0.000457	0.00908	CcSEcCtD
Lidocaine—Visual impairment—Carmustine—malignant glioma	0.000456	0.00905	CcSEcCtD
Lidocaine—Hypoaesthesia—Temozolomide—malignant glioma	0.000455	0.00903	CcSEcCtD
Lidocaine—Eye disorder—Carmustine—malignant glioma	0.000442	0.00878	CcSEcCtD
Lidocaine—Visual impairment—Temozolomide—malignant glioma	0.00044	0.00875	CcSEcCtD
Lidocaine—Flushing—Carmustine—malignant glioma	0.000439	0.00872	CcSEcCtD
Lidocaine—Eye disorder—Temozolomide—malignant glioma	0.000427	0.00849	CcSEcCtD
Lidocaine—Tinnitus—Temozolomide—malignant glioma	0.000426	0.00847	CcSEcCtD
Lidocaine—SCN2A—midbrain—malignant glioma	0.000425	0.0261	CbGeAlD
Lidocaine—Cardiac disorder—Temozolomide—malignant glioma	0.000424	0.00843	CcSEcCtD
Lidocaine—Flushing—Temozolomide—malignant glioma	0.000424	0.00843	CcSEcCtD
Lidocaine—Angiopathy—Temozolomide—malignant glioma	0.000414	0.00824	CcSEcCtD
Lidocaine—SCN2A—spinal cord—malignant glioma	0.000414	0.0254	CbGeAlD
Lidocaine—Immune system disorder—Temozolomide—malignant glioma	0.000413	0.0082	CcSEcCtD
Lidocaine—Erythema—Carmustine—malignant glioma	0.000412	0.00818	CcSEcCtD
Lidocaine—Procainamide—BCHE—malignant glioma	0.000411	0.138	CrCbGaD
Lidocaine—EGFR—brain—malignant glioma	0.00041	0.0252	CbGeAlD
Lidocaine—Chills—Temozolomide—malignant glioma	0.00041	0.00815	CcSEcCtD
Lidocaine—SCN3A—medulla oblongata—malignant glioma	0.000408	0.0251	CbGeAlD
Lidocaine—SCN10A—spinal cord—malignant glioma	0.0004	0.0245	CbGeAlD
Lidocaine—Back pain—Carmustine—malignant glioma	0.000398	0.00791	CcSEcCtD
Lidocaine—Erythema—Temozolomide—malignant glioma	0.000398	0.0079	CcSEcCtD
Lidocaine—Dysgeusia—Temozolomide—malignant glioma	0.000389	0.00774	CcSEcCtD
Lidocaine—Vision blurred—Carmustine—malignant glioma	0.000388	0.00771	CcSEcCtD
Lidocaine—Tremor—Carmustine—malignant glioma	0.000386	0.00766	CcSEcCtD
Lidocaine—Back pain—Temozolomide—malignant glioma	0.000385	0.00765	CcSEcCtD
Lidocaine—SCN4A—central nervous system—malignant glioma	0.00038	0.0233	CbGeAlD
Lidocaine—Agitation—Carmustine—malignant glioma	0.000378	0.00752	CcSEcCtD
Lidocaine—Vision blurred—Temozolomide—malignant glioma	0.000375	0.00745	CcSEcCtD
Lidocaine—SCN3A—midbrain—malignant glioma	0.000373	0.0229	CbGeAlD
Lidocaine—Tremor—Temozolomide—malignant glioma	0.000373	0.00741	CcSEcCtD
Lidocaine—Agitation—Temozolomide—malignant glioma	0.000365	0.00726	CcSEcCtD
Lidocaine—SCN3A—spinal cord—malignant glioma	0.000364	0.0224	CbGeAlD
Lidocaine—Angioedema—Temozolomide—malignant glioma	0.000363	0.00722	CcSEcCtD
Lidocaine—Convulsion—Carmustine—malignant glioma	0.000357	0.00709	CcSEcCtD
Lidocaine—Hypertension—Carmustine—malignant glioma	0.000355	0.00706	CcSEcCtD
Lidocaine—Chest pain—Carmustine—malignant glioma	0.00035	0.00696	CcSEcCtD
Lidocaine—Anxiety—Carmustine—malignant glioma	0.000349	0.00694	CcSEcCtD
Lidocaine—Convulsion—Temozolomide—malignant glioma	0.000345	0.00685	CcSEcCtD
Lidocaine—Hypertension—Temozolomide—malignant glioma	0.000343	0.00682	CcSEcCtD
Lidocaine—Confusional state—Carmustine—malignant glioma	0.000339	0.00673	CcSEcCtD
Lidocaine—SCN9A—brain—malignant glioma	0.000338	0.0208	CbGeAlD
Lidocaine—Anxiety—Temozolomide—malignant glioma	0.000337	0.00671	CcSEcCtD
Lidocaine—SCN2A—central nervous system—malignant glioma	0.000336	0.0206	CbGeAlD
Lidocaine—Oedema—Carmustine—malignant glioma	0.000336	0.00668	CcSEcCtD
Lidocaine—SCN2A—cerebellum—malignant glioma	0.000329	0.0202	CbGeAlD
Lidocaine—SLC22A5—retina—malignant glioma	0.000327	0.0201	CbGeAlD
Lidocaine—Confusional state—Temozolomide—malignant glioma	0.000327	0.0065	CcSEcCtD
Lidocaine—Anaphylactic shock—Temozolomide—malignant glioma	0.000325	0.00645	CcSEcCtD
Lidocaine—Oedema—Temozolomide—malignant glioma	0.000325	0.00645	CcSEcCtD
Lidocaine—SCN10A—central nervous system—malignant glioma	0.000324	0.0199	CbGeAlD
Lidocaine—Nervous system disorder—Temozolomide—malignant glioma	0.000318	0.00633	CcSEcCtD
Lidocaine—Hypotension—Carmustine—malignant glioma	0.000314	0.00624	CcSEcCtD
Lidocaine—Hyperhidrosis—Temozolomide—malignant glioma	0.000314	0.00624	CcSEcCtD
Lidocaine—Paraesthesia—Carmustine—malignant glioma	0.000302	0.00599	CcSEcCtD
Lidocaine—SCN4A—brain—malignant glioma	0.000302	0.0185	CbGeAlD
Lidocaine—Dyspnoea—Carmustine—malignant glioma	0.000299	0.00595	CcSEcCtD
Lidocaine—Somnolence—Carmustine—malignant glioma	0.000299	0.00593	CcSEcCtD
Lidocaine—SCN3A—central nervous system—malignant glioma	0.000295	0.0181	CbGeAlD
Lidocaine—SCN5A—central nervous system—malignant glioma	0.000295	0.0181	CbGeAlD
Lidocaine—Paraesthesia—Temozolomide—malignant glioma	0.000291	0.00579	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Carmustine—malignant glioma	0.00029	0.00576	CcSEcCtD
Lidocaine—Dyspnoea—Temozolomide—malignant glioma	0.000289	0.00575	CcSEcCtD
Lidocaine—SCN3A—cerebellum—malignant glioma	0.000289	0.0177	CbGeAlD
Lidocaine—Somnolence—Temozolomide—malignant glioma	0.000289	0.00573	CcSEcCtD
Lidocaine—CYP2A6—cerebellum—malignant glioma	0.000289	0.0177	CbGeAlD
Lidocaine—ABCB1—blood vessel—malignant glioma	0.000288	0.0177	CbGeAlD
Lidocaine—Pain—Carmustine—malignant glioma	0.000287	0.00571	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00028	0.00557	CcSEcCtD
Lidocaine—Pain—Temozolomide—malignant glioma	0.000278	0.00552	CcSEcCtD
Lidocaine—Feeling abnormal—Carmustine—malignant glioma	0.000277	0.0055	CcSEcCtD
Lidocaine—Feeling abnormal—Temozolomide—malignant glioma	0.000267	0.00532	CcSEcCtD
Lidocaine—SCN2A—brain—malignant glioma	0.000267	0.0164	CbGeAlD
Lidocaine—Urticaria—Temozolomide—malignant glioma	0.000258	0.00512	CcSEcCtD
Lidocaine—SCN10A—brain—malignant glioma	0.000257	0.0158	CbGeAlD
Lidocaine—Hypersensitivity—Carmustine—malignant glioma	0.000247	0.00492	CcSEcCtD
Lidocaine—Asthenia—Carmustine—malignant glioma	0.000241	0.00479	CcSEcCtD
Lidocaine—Hypersensitivity—Temozolomide—malignant glioma	0.000239	0.00475	CcSEcCtD
Lidocaine—SLC22A5—medulla oblongata—malignant glioma	0.000237	0.0145	CbGeAlD
Lidocaine—SCN3A—brain—malignant glioma	0.000235	0.0144	CbGeAlD
Lidocaine—CYP2A6—brain—malignant glioma	0.000234	0.0144	CbGeAlD
Lidocaine—SCN5A—brain—malignant glioma	0.000234	0.0144	CbGeAlD
Lidocaine—Asthenia—Temozolomide—malignant glioma	0.000233	0.00463	CcSEcCtD
Lidocaine—Dizziness—Carmustine—malignant glioma	0.000222	0.00441	CcSEcCtD
Lidocaine—CYP2D6—brainstem—malignant glioma	0.000219	0.0134	CbGeAlD
Lidocaine—SLC22A5—midbrain—malignant glioma	0.000216	0.0133	CbGeAlD
Lidocaine—Dizziness—Temozolomide—malignant glioma	0.000215	0.00427	CcSEcCtD
Lidocaine—Vomiting—Carmustine—malignant glioma	0.000214	0.00424	CcSEcCtD
Lidocaine—Rash—Carmustine—malignant glioma	0.000212	0.00421	CcSEcCtD
Lidocaine—Dermatitis—Carmustine—malignant glioma	0.000212	0.0042	CcSEcCtD
Lidocaine—SLC22A5—spinal cord—malignant glioma	0.000211	0.013	CbGeAlD
Lidocaine—Headache—Carmustine—malignant glioma	0.00021	0.00418	CcSEcCtD
Lidocaine—Vomiting—Temozolomide—malignant glioma	0.000206	0.0041	CcSEcCtD
Lidocaine—Rash—Temozolomide—malignant glioma	0.000205	0.00407	CcSEcCtD
Lidocaine—Dermatitis—Temozolomide—malignant glioma	0.000204	0.00406	CcSEcCtD
Lidocaine—Headache—Temozolomide—malignant glioma	0.000203	0.00404	CcSEcCtD
Lidocaine—Nausea—Carmustine—malignant glioma	0.000199	0.00396	CcSEcCtD
Lidocaine—CYP2D6—telencephalon—malignant glioma	0.000194	0.0119	CbGeAlD
Lidocaine—Nausea—Temozolomide—malignant glioma	0.000193	0.00383	CcSEcCtD
Lidocaine—ABCB1—embryo—malignant glioma	0.000172	0.0106	CbGeAlD
Lidocaine—SLC22A5—cerebellum—malignant glioma	0.000167	0.0103	CbGeAlD
Lidocaine—ABCB1—retina—malignant glioma	0.000152	0.00933	CbGeAlD
Lidocaine—CYP2B6—central nervous system—malignant glioma	0.000149	0.00913	CbGeAlD
Lidocaine—ABCB1—telencephalon—malignant glioma	0.00014	0.00858	CbGeAlD
Lidocaine—SLC22A5—brain—malignant glioma	0.000136	0.00834	CbGeAlD
Lidocaine—CYP2C8—brain—malignant glioma	0.000132	0.00808	CbGeAlD
Lidocaine—CYP2B6—brain—malignant glioma	0.000118	0.00725	CbGeAlD
Lidocaine—CYP3A4—central nervous system—malignant glioma	0.000112	0.00689	CbGeAlD
Lidocaine—CYP2D6—central nervous system—malignant glioma	0.00011	0.00678	CbGeAlD
Lidocaine—ABCB1—medulla oblongata—malignant glioma	0.00011	0.00674	CbGeAlD
Lidocaine—CYP2D6—cerebellum—malignant glioma	0.000108	0.00663	CbGeAlD
Lidocaine—ABCB1—midbrain—malignant glioma	0.0001	0.00616	CbGeAlD
Lidocaine—ABCB1—spinal cord—malignant glioma	9.79e-05	0.00601	CbGeAlD
Lidocaine—CYP2D6—brain—malignant glioma	8.77e-05	0.00538	CbGeAlD
Lidocaine—ABCB1—central nervous system—malignant glioma	7.94e-05	0.00488	CbGeAlD
Lidocaine—ABCB1—cerebellum—malignant glioma	7.77e-05	0.00477	CbGeAlD
Lidocaine—ABCB1—brain—malignant glioma	6.31e-05	0.00387	CbGeAlD
Lidocaine—EGFR—Signaling Pathways—NCOR1—malignant glioma	7.38e-06	6.14e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—BRAF—malignant glioma	7.35e-06	6.12e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—IDH1—malignant glioma	7.28e-06	6.06e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—RAF1—malignant glioma	7.28e-06	6.05e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—AKT2—malignant glioma	7.16e-06	5.95e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—FGF2—malignant glioma	7.13e-06	5.93e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—PIK3CB—malignant glioma	7.1e-06	5.91e-05	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—KRAS—malignant glioma	7.1e-06	5.91e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PDGFRA—malignant glioma	7.06e-06	5.88e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—SPHK1—malignant glioma	7.04e-06	5.86e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GSTT1—malignant glioma	6.99e-06	5.82e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—BCHE—malignant glioma	6.99e-06	5.82e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PIK3CB—malignant glioma	6.99e-06	5.81e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	6.93e-06	5.77e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PTGS2—malignant glioma	6.92e-06	5.76e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—SLC5A5—malignant glioma	6.9e-06	5.74e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CYP2C18—malignant glioma	6.9e-06	5.74e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PIK3CD—malignant glioma	6.88e-06	5.72e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—SPP1—malignant glioma	6.86e-06	5.7e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CXCL8—malignant glioma	6.83e-06	5.68e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—PIK3CA—malignant glioma	6.79e-06	5.65e-05	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	6.78e-06	5.64e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—BCL2—malignant glioma	6.77e-06	5.63e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IFNG—malignant glioma	6.71e-06	5.58e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	6.69e-06	5.57e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—MDM2—malignant glioma	6.67e-06	5.55e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—CAV1—malignant glioma	6.65e-06	5.54e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—RAF1—malignant glioma	6.65e-06	5.53e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GSTT1—malignant glioma	6.59e-06	5.48e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—FGF2—malignant glioma	6.58e-06	5.48e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—ERBB2—malignant glioma	6.58e-06	5.47e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—GSTP1—malignant glioma	6.57e-06	5.47e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTGS1—malignant glioma	6.55e-06	5.45e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—IDH2—malignant glioma	6.53e-06	5.43e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GSTT1—malignant glioma	6.53e-06	5.43e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	6.53e-06	5.43e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—IL2—malignant glioma	6.52e-06	5.43e-05	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—PIK3CA—malignant glioma	6.52e-06	5.43e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	6.51e-06	5.41e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TERT—malignant glioma	6.5e-06	5.41e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PIK3CB—malignant glioma	6.49e-06	5.4e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	6.47e-06	5.38e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—GSTP1—malignant glioma	6.42e-06	5.34e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CAT—malignant glioma	6.39e-06	5.32e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PDGFB—malignant glioma	6.34e-06	5.28e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—FGFR1—malignant glioma	6.31e-06	5.25e-05	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—AKT1—malignant glioma	6.28e-06	5.23e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CAT—malignant glioma	6.25e-06	5.2e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—HIF1A—malignant glioma	6.22e-06	5.17e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTGS1—malignant glioma	6.17e-06	5.14e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MDM2—malignant glioma	6.16e-06	5.12e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYP2B6—malignant glioma	6.14e-06	5.11e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—RAF1—malignant glioma	6.14e-06	5.11e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTGS1—malignant glioma	6.12e-06	5.09e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—CAV1—malignant glioma	6.1e-06	5.07e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	6.1e-06	5.07e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—BCHE—malignant glioma	6.09e-06	5.07e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—ERBB2—malignant glioma	6.07e-06	5.05e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CG—malignant glioma	6.06e-06	5.04e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PTEN—malignant glioma	6.04e-06	5.02e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—NCOR1—malignant glioma	6.04e-06	5.02e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—SLC5A5—malignant glioma	6.01e-06	5e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CAV1—malignant glioma	6.01e-06	5e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PIK3CB—malignant glioma	5.99e-06	4.99e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL1B—malignant glioma	5.98e-06	4.98e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL2—malignant glioma	5.96e-06	4.96e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KDR—malignant glioma	5.95e-06	4.95e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PTGS2—malignant glioma	5.94e-06	4.94e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	5.93e-06	4.93e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—NCOR1—malignant glioma	5.9e-06	4.91e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PPARG—malignant glioma	5.85e-06	4.87e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—BCHE—malignant glioma	5.74e-06	4.77e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—F2—malignant glioma	5.72e-06	4.76e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—FN1—malignant glioma	5.72e-06	4.76e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	5.72e-06	4.76e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—BCHE—malignant glioma	5.69e-06	4.73e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—SLC5A5—malignant glioma	5.67e-06	4.72e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—BAD—malignant glioma	5.65e-06	4.7e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	5.64e-06	4.69e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—SLC5A5—malignant glioma	5.62e-06	4.67e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—IDH1—malignant glioma	5.62e-06	4.67e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PTEN—malignant glioma	5.61e-06	4.67e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NOTCH1—malignant glioma	5.6e-06	4.66e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GSTT1—malignant glioma	5.58e-06	4.64e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GSTP1—malignant glioma	5.56e-06	4.63e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CG—malignant glioma	5.56e-06	4.62e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—AKT1—malignant glioma	5.55e-06	4.62e-05	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—RAF1—malignant glioma	5.54e-06	4.61e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CD80—malignant glioma	5.49e-06	4.56e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CG—malignant glioma	5.48e-06	4.56e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—APC—malignant glioma	5.48e-06	4.56e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—SPHK1—malignant glioma	5.43e-06	4.52e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—EGF—malignant glioma	5.41e-06	4.5e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CAT—malignant glioma	5.41e-06	4.5e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PTPN11—malignant glioma	5.38e-06	4.48e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PPARG—malignant glioma	5.36e-06	4.46e-05	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—AKT1—malignant glioma	5.33e-06	4.43e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CD—malignant glioma	5.33e-06	4.43e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYP2C18—malignant glioma	5.32e-06	4.43e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	5.31e-06	4.42e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	5.26e-06	4.38e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTGS1—malignant glioma	5.23e-06	4.35e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	5.21e-06	4.33e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PTEN—malignant glioma	5.18e-06	4.31e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—BRAF—malignant glioma	5.15e-06	4.28e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—NCOR1—malignant glioma	5.11e-06	4.25e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—STAT3—malignant glioma	5.02e-06	4.17e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—AKT2—malignant glioma	5.01e-06	4.17e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CAV1—malignant glioma	4.92e-06	4.09e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CD—malignant glioma	4.88e-06	4.06e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—BCHE—malignant glioma	4.86e-06	4.04e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GSTP1—malignant glioma	4.84e-06	4.03e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CD—malignant glioma	4.81e-06	4.01e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CAV1—malignant glioma	4.81e-06	4e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—SLC5A5—malignant glioma	4.8e-06	3.99e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CAT—malignant glioma	4.71e-06	3.92e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—KRAS—malignant glioma	4.71e-06	3.92e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CB—malignant glioma	4.64e-06	3.86e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—STAT3—malignant glioma	4.63e-06	3.85e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—FGF2—malignant glioma	4.61e-06	3.84e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PTGS2—malignant glioma	4.6e-06	3.83e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	4.59e-06	3.82e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GSTP1—malignant glioma	4.57e-06	3.8e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	4.54e-06	3.78e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GSTP1—malignant glioma	4.53e-06	3.77e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	4.5e-06	3.74e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CG—malignant glioma	4.48e-06	3.73e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—NCOR1—malignant glioma	4.45e-06	3.7e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CAT—malignant glioma	4.44e-06	3.7e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CAT—malignant glioma	4.4e-06	3.66e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CG—malignant glioma	4.38e-06	3.64e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—PIK3CA—malignant glioma	4.33e-06	3.6e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PPARG—malignant glioma	4.33e-06	3.6e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MDM2—malignant glioma	4.31e-06	3.59e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—KRAS—malignant glioma	4.31e-06	3.58e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GSTT1—malignant glioma	4.31e-06	3.58e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MYC—malignant glioma	4.3e-06	3.58e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—RAF1—malignant glioma	4.3e-06	3.58e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PIK3CA—malignant glioma	4.26e-06	3.54e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CB—malignant glioma	4.26e-06	3.54e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—ERBB2—malignant glioma	4.25e-06	3.54e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PPARG—malignant glioma	4.23e-06	3.52e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PTGS2—malignant glioma	4.22e-06	3.51e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CB—malignant glioma	4.2e-06	3.49e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—NCOR1—malignant glioma	4.2e-06	3.49e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CAV1—malignant glioma	4.17e-06	3.47e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—NCOR1—malignant glioma	4.16e-06	3.46e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTGS1—malignant glioma	4.04e-06	3.36e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CXCL8—malignant glioma	4.03e-06	3.36e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PTEN—malignant glioma	4.01e-06	3.34e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	3.98e-06	3.31e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—KRAS—malignant glioma	3.98e-06	3.31e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PIK3CA—malignant glioma	3.96e-06	3.29e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CD—malignant glioma	3.94e-06	3.28e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	3.92e-06	3.26e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GSTP1—malignant glioma	3.87e-06	3.22e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CASP3—malignant glioma	3.86e-06	3.21e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IL2—malignant glioma	3.85e-06	3.21e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CD—malignant glioma	3.85e-06	3.2e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CG—malignant glioma	3.79e-06	3.16e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CAT—malignant glioma	3.76e-06	3.13e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—BCHE—malignant glioma	3.75e-06	3.12e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—SLC5A5—malignant glioma	3.71e-06	3.08e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PTEN—malignant glioma	3.68e-06	3.06e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PPARG—malignant glioma	3.66e-06	3.05e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PIK3CA—malignant glioma	3.65e-06	3.04e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MMP9—malignant glioma	3.65e-06	3.03e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CAV1—malignant glioma	3.63e-06	3.02e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PTEN—malignant glioma	3.63e-06	3.02e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—NCOR1—malignant glioma	3.55e-06	2.96e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—AKT1—malignant glioma	3.54e-06	2.94e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—AKT1—malignant glioma	3.48e-06	2.89e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CB—malignant glioma	3.43e-06	2.86e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CAV1—malignant glioma	3.42e-06	2.85e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTGS2—malignant glioma	3.4e-06	2.83e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CAV1—malignant glioma	3.39e-06	2.82e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CB—malignant glioma	3.36e-06	2.79e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CD—malignant glioma	3.34e-06	2.78e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTGS2—malignant glioma	3.33e-06	2.77e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CG—malignant glioma	3.31e-06	2.75e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—VEGFA—malignant glioma	3.28e-06	2.73e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—STAT3—malignant glioma	3.24e-06	2.7e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	3.24e-06	2.7e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—AKT1—malignant glioma	3.23e-06	2.69e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PPARG—malignant glioma	3.19e-06	2.65e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CG—malignant glioma	3.12e-06	2.59e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CG—malignant glioma	3.09e-06	2.57e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MYC—malignant glioma	3.01e-06	2.51e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PPARG—malignant glioma	3.01e-06	2.5e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GSTP1—malignant glioma	2.98e-06	2.48e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—AKT1—malignant glioma	2.98e-06	2.48e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PPARG—malignant glioma	2.98e-06	2.48e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTEN—malignant glioma	2.97e-06	2.47e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CB—malignant glioma	2.91e-06	2.42e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CD—malignant glioma	2.91e-06	2.42e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CAT—malignant glioma	2.9e-06	2.42e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTEN—malignant glioma	2.9e-06	2.41e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CAV1—malignant glioma	2.9e-06	2.41e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTGS2—malignant glioma	2.88e-06	2.4e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CA—malignant glioma	2.83e-06	2.36e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KRAS—malignant glioma	2.78e-06	2.32e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	2.77e-06	2.3e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—NCOR1—malignant glioma	2.74e-06	2.28e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CD—malignant glioma	2.74e-06	2.28e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CD—malignant glioma	2.71e-06	2.26e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CG—malignant glioma	2.64e-06	2.2e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CA—malignant glioma	2.59e-06	2.16e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CA—malignant glioma	2.56e-06	2.13e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PPARG—malignant glioma	2.55e-06	2.12e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CB—malignant glioma	2.53e-06	2.11e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTEN—malignant glioma	2.51e-06	2.09e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTGS2—malignant glioma	2.51e-06	2.09e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TP53—malignant glioma	2.47e-06	2.06e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CB—malignant glioma	2.39e-06	1.99e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CB—malignant glioma	2.37e-06	1.97e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTGS2—malignant glioma	2.37e-06	1.97e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTGS2—malignant glioma	2.34e-06	1.95e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CD—malignant glioma	2.32e-06	1.93e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—AKT1—malignant glioma	2.31e-06	1.92e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CAV1—malignant glioma	2.24e-06	1.86e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTEN—malignant glioma	2.19e-06	1.82e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—AKT1—malignant glioma	2.12e-06	1.76e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CA—malignant glioma	2.09e-06	1.74e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—AKT1—malignant glioma	2.09e-06	1.74e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTEN—malignant glioma	2.06e-06	1.72e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CA—malignant glioma	2.05e-06	1.7e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTEN—malignant glioma	2.04e-06	1.7e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CG—malignant glioma	2.04e-06	1.69e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CB—malignant glioma	2.02e-06	1.68e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTGS2—malignant glioma	2e-06	1.67e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PPARG—malignant glioma	1.97e-06	1.64e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CD—malignant glioma	1.79e-06	1.49e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CA—malignant glioma	1.77e-06	1.47e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTEN—malignant glioma	1.75e-06	1.45e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—AKT1—malignant glioma	1.71e-06	1.42e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—AKT1—malignant glioma	1.67e-06	1.39e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CB—malignant glioma	1.56e-06	1.3e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTGS2—malignant glioma	1.55e-06	1.29e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CA—malignant glioma	1.54e-06	1.28e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CA—malignant glioma	1.46e-06	1.21e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—AKT1—malignant glioma	1.45e-06	1.2e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CA—malignant glioma	1.44e-06	1.2e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTEN—malignant glioma	1.35e-06	1.12e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—AKT1—malignant glioma	1.26e-06	1.05e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CA—malignant glioma	1.23e-06	1.03e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—AKT1—malignant glioma	1.19e-06	9.89e-06	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—AKT1—malignant glioma	1.18e-06	9.8e-06	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—AKT1—malignant glioma	1.01e-06	8.38e-06	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CA—malignant glioma	9.51e-07	7.92e-06	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—AKT1—malignant glioma	7.77e-07	6.47e-06	CbGpPWpGaD
